Day: August 28, 2025

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Written by Customer Service on August 28, 2025. Posted in Earnings Releases And Operating Results.

Ramat Gan, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced financial results and clinical updates for H1, 2025. Clinical & Development Milestones Achieved Namodenoson Drug Candidate – Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone The Phase 2a study (NCT06387342) is a multicenter, open-label trial enrolling patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one line of prior therapy. The study is evaluating the safety (primary endpoint), clinical activity, and pharmacokinetics (PK) of Namodenoson in this patient population. Participants...

CF Energy Announces Financial Results For the Three-month and Six-month periods ended June 30, 2025

Written by Customer Service on August 28, 2025. Posted in Earnings Releases And Operating Results.

TORONTO, Aug. 28, 2025 (GLOBE NEWSWIRE) — CF Energy Corp. (TSX-V: CFY) (“CF Energy” or the “Company”, together with its subsidiaries, the “Group”), an energy provider in the People’s Republic of China (the ”PRC” or “China”), announces that the Company has filed its unaudited interim consolidated financial results for the three-month and six-month periods ended June 30, 2025. The unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis (“MD&A”) can be downloaded from www.sedarplus.com or from the Company’s website at www.cfenergy.com. The unaudited condensed interim consolidated financial statements have been prepared in conformity with IFRS Accounting Standards as issued by the International Accounting Standards Board (“IASB”) (collectively, “IFRS Accounting Standards”)....

Alarum Technologies Announces Second Quarter 2025 Results

Written by Customer Service on August 28, 2025. Posted in Earnings Releases And Operating Results.

Deepening collaborations with major global customers while accelerating investments intechnology and talent to cement Alarum’s key positioning in the AI value chain Q2 2025 revenues of $8.8 million, net profit of $0.3 million, and Adjusted EBITDA of $1.0 million TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) — Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of web data collection solutions, today announced financial results for the six- and three-month periods ended June 30, 2025. Management Commentary “Our focus and progress this quarter, as well as our outlook, are mainly driven by very strong demand for data from major global players in the artificial intelligence (AI) segment for training large language and other foundational models,” commented Shahar Daniel, Chief Executive Officer...

NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results

Written by Customer Service on August 28, 2025. Posted in Earnings Releases And Operating Results.

TORONTO and HAIFA, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the second quarter ended June 30, 2025 (“Q2”), and provide a corporate update on its recent activities and upcoming milestones. The Company’s full set of unaudited condensed interim consolidated financial statements for the six months ended June 30, 2025, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca. Key Business HighlightsC$2.3 million raised through Private Placement: On April 10, 2025, NurExone...

Easily Integrate Position, Navigation and Timing Technology With Microchip’s Portfolio of GNSS Disciplined Oscillator Modules

Written by Customer Service on August 28, 2025. Posted in Public Companies.

These high-performance, small-form-factor timing systems are designed for defense applications in GNSS-denied environments CHANDLER, Ariz., Aug. 28, 2025 (GLOBE NEWSWIRE) — Aerospace and defense applications rely on Position, Navigation and Timing (PNT) technology for mission-critical accuracy and reliability. However, integrating PNT into a design requires extensive domain knowledge in this area. To fast track the development process, Microchip Technology (Nasdaq: MCHP) today announces its portfolio of GNSS Disciplined Oscillator (GNSSDO) Modules that integrate the company’s renowned embedded atomic clock and oscillator technologies, including the Chip-Scale Atomic Clock (CSAC), Miniature Atomic Clock (MAC) and Oven-Controlled Quartz Crystal Oscillators (OCXOs). The GNSSDO modules process reference signals from GNSS or an alternative...

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Written by Customer Service on August 28, 2025. Posted in Public Companies.

KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase 3 trial design for myasthenia gravis supports clear and rapid path to BLA Webcast today August 28th, at 11 am ET EMERYVILLE, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, will host a virtual KOL event today to highlight its neuroimmunology CAR T franchise in stiff person syndrome (SPS) and myasthenia gravis (MG). As part of this event, the Company will share details of its Phase 3 clinical trial design in MG; positive longer-term follow-up data from MG and SPS compassionate use patients1...

Ollie’s Bargain Outlet Holdings, Inc. Announces Second Quarter Fiscal 2025 Results

Written by Customer Service on August 28, 2025. Posted in Earnings Releases And Operating Results.

Store Openings, Sales, and Earnings Ahead of Expectations Net Sales Increased 17.5% and Earnings Per Share Increased 25.0% Raising Fiscal 2025 Sales and Earnings Outlook HARRISBURG, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) — Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) today announced financial results for the second quarter fiscal 2025 ended August 2, 2025. “We had a very strong second quarter and are operating with the wind in our sails,” said Eric van der Valk, President and Chief Executive Officer. “We are driving the business to new heights through improved planning, coordination, and execution across the organization. New store openings, total sales, comparable store sales, and earnings were all ahead of our expectations in the quarter and we are raising our full-year outlook across the board.” Mr. van...

Unaudited financial report for the second quarter and 6 months of 2025

Written by Customer Service on August 28, 2025. Posted in Earnings Releases And Operating Results.

The main business activity of Trigon Property Development AS is real estate development. As at 30.06.2025, AS Trigon Property Development owned one development project with an area of 13.2 hectares in the City of Pärnu, Estonia. A commercial, industrial and logistics park is planned on this area. The Company’s objective is to find companies willing to bring their business activities (industry, logistics) to the development project area of AS Trigon Property Development in Pärnu, which would add value to the land plots owned by the Company. As the main purpose of the company is to sell existing land plots, investment property was recognized as inventories. In the third quarter of 2024, a 0.09-hectare transportation purpose land was sold for 31,920 euros (excluding VAT). In the fourth quarter of 2024, a 0.70-hectare property was sold for...

CTW Launches Pre-Registration for Simulation Game Adaptation of Hit Anime The Apothecary Diaries

Written by Customer Service on August 28, 2025. Posted in Public Companies.

TOKYO, Aug. 28, 2025 (GLOBE NEWSWIRE) — CTW Cayman (Nasdaq: CTW) (“CTW” or “the Company”), a leading game platform company providing global access to web-based games through its flagship HTML5 platform, G123.jp, which showcases a diverse selection of free-to-play games inspired by popular Japanese animations, today announced that pre-registration is now underway for The Apothecary Diaries Palace Chronicles, a simulation game based on the popular anime The Apothecary Diaries. The Apothecary Diaries Palace Chronicles is a simulation game based on the TV anime The Apothecary Diaries. Players will train the protagonist, Maomao, and take on various cases and dilemmas occurring within the palace and pleasure district. Playable directly on web browsers, no installation is needed. Whether on smartphone, tablet, or PC, players can easily...

MAAS Announces Strategic Expansion into Healthcare and Wellness with Acquisition of Carve Group Ltd

Written by Customer Service on August 28, 2025. Posted in Mergers And Acquisitions.

CHENGDU, China, Aug. 28, 2025 (GLOBE NEWSWIRE) — Maase Inc. (NASDAQ: MAAS) (“MAAS” or the “Company”) today announced the successful completion of its strategic acquisition of 100% equity interests in Carve Group Ltd (the “Target Company” or the “Carve Group”). The transaction, previously disclosed in the Company’s Form 6-K filed on July 29, 2025, was formally consummated on August 27, 2025. Pursuant to the transaction agreement dated July 28, 2025, MAAS has acquired all equity interests in the Target Company from its existing shareholders, Golden Brighter Limited (“GBL”), WJ Management Company Limited (“WJM”), and Union Chief Limited (“UCL”) (collectively, the “Sellers”). As consideration, MAAS issued an aggregate of 195,894,609 Class A ordinary shares with a par value of US$0.09 per share (the “Consideration Shares”), at an issue...

Day: August 28, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals